BGI SENTIS™ Comprehensive Hereditary Cancer Panel
Introduction
BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.
BGI’s Comprehensive Hereditary Cancer Panels provides information on 79 genes associated with 24 different types of hereditary cancer including some of the most commonly occurring cancers such as hereditary breast, ovarian, colorectal, pancreatic, prostate, and stomach cancer. BGI detects different alterations including germline SNV, Indels, and CNV.
SUITABLE FOR:
Patients suspected of being at increased risk of hereditary cancer
TA TIME:
14 - 26 days
SAMPLE:
Peripheral blood, DNA, Saliva
TECHNOLOGY:
Target region capture, High-throughput sequencing
List of Hereditary Cancers Panels
Why Choose BGI SENTIS™ Hereditary Cancer Screening?
- Comprehensive – whole-exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements
- Robust – Large gene rearrangements are verified by qPCR
- Convenient – test from blood or saliva; DNA is also accepted
- Professional – state-of-the-art variant database ensures up-to-date analysis and interpretation.
Workflow
Ordering the BGI SENTIS™ Hereditary Cancer Screening is easy.
STEP 1
Physician orders test
STEP 2
Blood or saliva sample collected
STEP 3
Sample shipped to BGI and analyzed
STEP 4
Results sent to physician